These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36333972)

  • 1. AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials.
    Zhou Y; Zhao Y; Cicconetti G; Mu Y; Yuan Y; Wang L; Penugonda S; Salman Z
    Pharm Stat; 2023 Mar; 22(2):300-311. PubMed ID: 36333972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.
    Lin R; Yuan Y
    Biostatistics; 2020 Oct; 21(4):807-824. PubMed ID: 30984972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
    Ji Y; Wang SJ
    J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.
    Wheeler GM; Sweeting MJ; Mander AP
    Stat Med; 2017 Jul; 36(16):2499-2513. PubMed ID: 28295513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.
    Kojima M
    BMC Med Res Methodol; 2022 Apr; 22(1):97. PubMed ID: 35382745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
    Zhang Y; Kutner M; Chen Z
    Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET.
    Zhao Y; Liu R; Takeda K
    Pharm Stat; 2023; 22(3):440-460. PubMed ID: 36514849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated titration designs for phase I clinical trials in oncology.
    Simon R; Freidlin B; Rubinstein L; Arbuck SG; Collins J; Christian MC
    J Natl Cancer Inst; 1997 Aug; 89(15):1138-47. PubMed ID: 9262252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
    Pallmann P; Wan F; Mander AP; Wheeler GM; Yap C; Clive S; Hampson LV; Jaki T
    Clin Trials; 2020 Apr; 17(2):147-156. PubMed ID: 31856600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
    Zhang L; Yuan Y
    Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
    Labrenz J; Edelmann D; Heitmann JS; Salih HR; Kopp-Schneider A; Schlenk RF
    Pharm Stat; 2023 Mar; 22(2):236-247. PubMed ID: 36285348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
    Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
    Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
    Yuan Y; Lin R; Li D; Nie L; Warren KE
    Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.